Benzinga | Feb 23, 2021 08:26AM EST

Rubius Therapeutics Says Continues To Enroll Patients In Second Phase 1 Arm Of RTX-240 Clinical Trial; Says Expects To Dose First Patient In RTX-321 Clinical Trial Of HPV 16-Positive Tumors In 2021

Anticipated 2021 Catalysts and Operational Objectives

* Present additional clinical data from the Phase 1 RTX-240 solid tumor trial in early 2021

* Continue to enroll patients in the second Phase 1 arm of the RTX-240 clinical trial in patients with relapsed/refractory AML

* Dose the first patient in the RTX-321 clinical trial in HPV 16-positive tumors

* Continue to produce cGMP material for the RTX-240 and RTX-321 clinical trials

* Present an integrated clinical program for RTX-240, including plans for expansion cohorts, and plans for the Company's oncology pipeline